ライフサイエンスコーパス: STEMI

1 STEMI and the lack of coronary revascularization determi

2 STEMI-SCAD represents an important STEMI subset, particu

3 bility, NSTEMI: 19.7% versus 11.4%, P<0.001; STEMI: 14.8% versus 6.4%, P<0.001; impaired functional m

4 irment, NSTEMI: 20.6% versus 14.3%, P<0.001; STEMI: 20.6% versus 12.4%, P=0.001; activities of daily

5 bility, NSTEMI: 44.5% versus 30.7%, P<0.001; STEMI: 39.4% versus 22.0%, P<0.001).

6 than men (NSTEMI: 82.1 versus 81.3, P<0.001; STEMI: 82.2 versus 80.6, P<0.001) and had lower rates of

7 mmonly (NSTEMI: 55.6% versus 63.6%, P<0.001; STEMI: 87.3% versus 93.3%, P=0.01).

8 structive coronary disease (NSTEMI: P<0.001; STEMI: P=0.02), driven by lower rates of 3-vessel or lef

9 low-dose regimen was administered in 1,068 (STEMI, n = 519; NSTE-ACS, n = 549) patients.

10 sis of first-time MI (54.9% NSTEMI and 45.1% STEMI).

11 We included 11543 STEMI and 8470 NSTEMI patients who underwent PCI in the

12 ospital mortality, achievement of at least 2 STEMI care metrics was associated with significantly red

13 More than 1 of 20 STEMI presents prehospital SCA after EMS arrival.

14 Among 5,208 STEMI patients, SCAD was present in 53 (1%; 93% female).

15 Among 13 253 STEMI patients analyzed, 749 (5.6%) presented EMS-witnes

16 ased strategies at our hospital to improve 3 STEMI care metrics: (1) prompt guideline-directed medica

17 centage with achievement of zero, 1, 2, or 3 STEMI care metrics was 7.1%, 24.1%, 43.8%, and 25.1%; an

18 Methods and Results We identified 169 505 STEMI patients in the Chest Pain-Myocardial Infarction R

19 ry PCI for the presence of QW (early) in 515 STEMI patients.

20 A total of 42 645 and 171 545 STEMI hospitalizations were identified as having Medicai

21 tients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metro

22 disease than men (STEMI: 38.8% versus 58.7%; STEMI: 24.3% versus 32.1%), and underwent revascularizat

23 e were 43 hospitals with 1976 AIS and 59 823 STEMI patients.

24 del used to combine the gene expression in a STEMI vs healthy donors score showed an AUC of 0.95.

25 of STEMI care on clinical outcomes within a STEMI system of care is unknown.

26 pt study, we defined two groups (1) an acute STEMI group (n = 6, 83% male, age 54 +/- 12 years) compl

27 METHODS AND Patients who sustained an acute STEMI were enrolled in a cohort study.

28 Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive

29 o presented between 2009 and 2014 with acute STEMI were combined with population data to generate inc

30 aterials and Methods Participants with acute STEMI were prospectively enrolled from May 11, 2011, to

31 rst overall survival (log-rank P=0.04) after STEMI during a median follow-up of 5.2 (3.6, 6.9) years

32 underwent cardiac MRI 2.2 days +/- 1.9 after STEMI.

33 eling and more impaired LV deformation after STEMI compared with those with normal BMI, amid similar

34 rience recurrent cardiovascular events after STEMI.

35 scharge, women developed heart failure after STEMI (women, 22.5%, versus men, 14.9%) as well as after

36 risk to develop de novo heart failure after STEMI and women with de novo heart failure have worse su

37 nd reduce progression to heart failure after STEMI are needed.

38 ined improvements in systolic function after STEMI.

39 a key feature to explain mortality gap after STEMI among women and men.

40 te heart failure, and related outcomes after STEMI in patients with no prior history of heart failure

41 bstruction (MVO), and adverse outcomes after STEMI.

42 ndependent predictor of worse outcomes after STEMI.

43 e nonculprit artery in the early phase after STEMI and determine the real prevalence of microvascular

44 We conclude that plasma profiling after STEMI may help identify patients with a greater likeliho

45 telet inhibition during the first year after STEMI.

46 eart failure in the subsequent 5 years after STEMI or NSTEMI, even after accounting for differences i

47 ective multicenter cardiac MRI studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) inc

48 des infarctus du myocarde) that enrolls all STEMI managed by EMS in the Greater Paris Area, includin

49 need for establishing COVID-19 status in all STEMI cases.

50 Among STEMI patients with multivessel disease, the benefit of

51 both NSTEMI (11.0% versus 7.8%, P=0.04) and STEMI (22.6% versus 14.8%, P=0.02).

52 type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%).

53 eated within target time windows for AIS and STEMI (median DTN time <60 minutes: 21% [interquartile r

54 pathophysiological mechanisms in NSTEMI and STEMI.

55 n a relatively short time period in anterior STEMI.

56 infarct size in patients with large anterior STEMI.

57 trial, we assigned 50 patients with anterior STEMI to LV unloading by using the Impella CP followed b

58 Compared with STEMI-ATH, STEMI-SCAD patients were younger (age 49 +/- 10 years vs

59 es of STEMI-SCAD with STEMI atherosclerosis (STEMI-ATH).

60 s of acute coronary syndrome, including both STEMI and NSTEMI, but relative and absolute reductions w

61 ber of PCI procedures for patients with both STEMI (438 PCI procedures per week in 2019 vs 346 by the

62 iated cytokines were largely not affected by STEMI, except for pro-inflammatory cytokines IL-6, IL-18

63 of cytokine clusters affected differently by STEMI now permits investigation of their differential co

64 isson distribution were calculated comparing STEMI rates between smokers and nonsmokers stratified by

65 consecutive patients admitted with confirmed STEMI treated with primary percutaneous coronary interve

66 Consecutive STEMI patients were retrospectively analyzed (2003 to 20

67 model may serve as an example for developing STEMI systems of care in other low- to middle-income cou

68 We quantified the impact of different STEMI treatment strategies on patient outcomes and provi

69 The DTU-STEMI pilot trial (Door-To-Unload in STEMI Pilot Trial)

70 The DTU-STEMI pilot trial did not identify prohibitive safety si

71 Forty-eight STEMI patients underwent CMR at 4 +/- 2 days.

72 Forty-eight STEMI patients were prospectively recruited and underwen

73 11,546 eligible STEMI patients between 2008 and 2015 were identified.

74 spital performance is correlated on emergent STEMI and AIS care is unknown.

75 Expanding STEMI systems of care from a singular focus on door-to-b

76 r SCA were age, heart failure, and extensive STEMI, while male sex and cardiovascular risk factors we

77 actors, symptoms of heart failure, extensive STEMI, and short pain onset-to-call and call-to-EMS arri

78 SCAD prevalence was 19% in female STEMI patients age <=50 years.

79 A reference first STEMI group (n = 203) who arrived outside the randomizat

80 Patients presenting with their first STEMI and early QW in the ECG had smaller myocardial sal

81 Patients with their first STEMI were prospectively randomized to either diagnostic

82 ional Inpatient Sample from 2012 to 2015 for STEMI hospitalizations with Medicaid or private insuranc

83 rvival was 98% for STEMI-SCAD versus 84% for STEMI-ATH; p < 0.001.

84 The 3-year survival was 98% for STEMI-SCAD versus 84% for STEMI-ATH; p < 0.001.

85 a historical cohort of patients admitted for STEMI during the analogous time period (February 21 to A

86 A total of 26 patients were admitted for STEMI during the study period, and 7 (26.9%) of these pa

87 (Primary Angioplasty for STEMI During COVID-19 Pandemic [ISACS-STEMI COVID-19] Re

88 primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be p

89 All hospitalizations for STEMI in the United States from January 1, 2003, to Dece

90 improve patient-centered decision-making for STEMI patients.

91 reat Multivessel Disease after Early PCI for STEMI (COMPLETE) trials.

92 eat Multi-vessel Disease After Early PCI for STEMI) trial demonstrated that staged nonculprit lesion

93 eat Multi-vessel Disease After Early PCI for STEMI) trial, angiography-guided percutaneous coronary i

94 eat Multi-Vessel Disease After Early PCI for STEMI), we performed optical coherence tomography of at

95 tients who underwent successful stenting for STEMI and had left ventricular dysfunction (ejection fra

96 the largest study of cell-based therapy for STEMI completed in the United States and provides eviden

97 erformance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) time for AIS, with and wi

98 OVID-19 and low likelihood of mortality from STEMI and use of preventive strategies such as preproced

99 ave resulted in a decrease in mortality from STEMI.

100 ofile highlights five genes able to identify STEMI patients and to discriminate them in the backgroun

101 STEMI-SCAD represents an important STEMI subset, particularly among younger women, characte

102 are offers an opportunity to further improve STEMI outcomes.

103 In STEMI-SCAD, acute revascularization included percutaneou

104 In STEMI-SCAD, the culprit artery was more commonly left ma

105 for all primary outcomes after adjustment in STEMI.

106 risk of death during hospitalization but in STEMI patients a lower HDL-C was paradoxically associate

107 The primary outcome did not differ in STEMI or NSTE-ACS patients who received or did not recei

108 d organizations involved with improvement in STEMI care in LMICs, it also provides some specific targ

109 ted with a significantly greater increase in STEMI rate for women than men (IRR: 6.62; 95% confidence

110 Acute revascularization was lower in STEMI-SCAD (70% vs. 97%); p < 0.001.

111 with a worse prognosis after primary PCI in STEMI.

112 ent, this difference remained significant in STEMI (adjusted odds ratio, 1.42 [95% CI, 1.24-1.64]) bu

113 port the use of routine deferred stenting in STEMI patients treated with primary PCI.

114 changes in LV function in the longer term in STEMI patients complicated by LV dysfunction.

115 pproved indication of reperfusion therapy in STEMI (streptokinase, tenecteplase, alteplase, and retep

116 The DTU-STEMI pilot trial (Door-To-Unload in STEMI Pilot Trial) represents the first exploratory stud

117 associated cytokines that are upregulated in STEMI and form correlative clusters.

118 oon time add incremental prognostic value in STEMI care.

119 to identify and understand the variation in STEMI outcomes by insurance status.

120 ST segment elevation myocardial infarction (STEMI) and 42 control subjects.

121 ST-segment elevation myocardial infarction (STEMI) and is associated with adverse outcomes.

122 ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD).

123 ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarctio

124 ST-segment elevation myocardial infarction (STEMI) care are formidable in low- to middle-income coun

125 ST-segment-elevation myocardial infarction (STEMI) care have traditionally focused on improving door

126 ST-segment elevation myocardial infarction (STEMI) caused by type 1 myocardial infarction in patient

127 ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock.

128 ST-segment elevation myocardial infarction (STEMI) complicated by symptoms of acute de novo heart fa

129 ST-segment-elevation myocardial infarction (STEMI) decreased drastically, mainly through reduction i

130 ST-segment elevation myocardial infarction (STEMI) from accessing the emergency system, with subsequ

131 ST-segment-elevation myocardial infarction (STEMI) has been demonstrated.

132 ST-segment-elevation myocardial infarction (STEMI) has been widely used; however, recent trials have

133 in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria.

134 ST-segment-elevation myocardial infarction (STEMI) have multivessel disease.

135 ST-segment-elevation myocardial infarction (STEMI) in context of the coronavirus disease 2019 (COVID

136 ST-segment-elevation myocardial infarction (STEMI) in particular is increasing at an unprecedented r

137 ST-segment elevation myocardial infarction (STEMI) in settings where health-care resources are scarc

138 ST-segment elevation myocardial infarction (STEMI) is the most acute manifestation of coronary arter

139 ST-segment elevation myocardial infarction (STEMI) may not be uniform over time, which may affect th

140 ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and

141 ST-segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary

142 ating an ST-elevation myocardial infarction (STEMI) presentation, stress cardiomyopathy, non-ischemic

143 ST-segment elevation myocardial infarction (STEMI) relates to smaller infarct size and preserved lon

144 ST-segment elevation myocardial infarction (STEMI) remains a significant global health problem.

145 ST-segment elevation myocardial infarction (STEMI) remains uncertain.

146 -ST-segment-elevation myocardial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstabl

147 ST-segment-elevation myocardial infarction (STEMI) undergoing PCI.

148 nts with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interven

149 ST-segment-elevation myocardial infarction (STEMI) victims remain at risk for infarct expansion, hea

150 ST-segment elevation myocardial infarction (STEMI), a gene-by-gene analysis of the platelet gene exp

151 ST-segment-elevation myocardial infarction (STEMI), infarct size correlates directly with heart fail

152 ified as ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), myocardial infarction of unk

153 ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the

154 ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (P

155 ST-segment-elevation myocardial infarction (STEMI), though use in recent practice is not well descri

156 ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either isch

157 ST-segment-elevation myocardial infarction (STEMI).

158 ST-segment elevation myocardial infarction (STEMI).

159 ST-segment-elevation myocardial infarction (STEMI).

160 ST-segment elevation myocardial infarction (STEMI).

161 ST-segment-elevation myocardial infarction (STEMI).

162 ST-segment elevation myocardial infarction (STEMI).

163 ST-segment elevation myocardial infarction (STEMI).

164 nts with ST-elevation myocardial infarction (STEMI).

165 ST-segment-elevation myocardial infarction (STEMI).

166 ST-segment elevation myocardial infarction (STEMI).

167 ST-segment elevation myocardial infarction (STEMI).

168 ST-segment elevation myocardial infarction (STEMI); however, once STEMI occurs, smoking has been ass

169 (ST-segment-elevation myocardial infarction [STEMI] and non-STEMI [NSTEMI]) and subsequently evaluate

170 (ST-segment elevation myocardial infarction [STEMI], n = 399; non-ST-segment elevation acute coronary

171 perintensity was associated with the initial STEMI severity, adverse remodeling, and long-term health

172 ty for STEMI During COVID-19 Pandemic [ISACS-STEMI COVID-19] Registry; NCT04412655).

173 The ISACS-STEMI COVID-19 registry aims to estimate the true impact

174 The Mission: Lifeline STEMI Systems Accelerator program, implemented in 16 US

175 boration of investigators interested in LMIC STEMI care have tried to create a consensus document tha

176 the pharmaco-invasive strategy for managing STEMI on 30-day patient mortality and individual provide

177 s of 3-vessel or left main disease than men (STEMI: 38.8% versus 58.7%; STEMI: 24.3% versus 32.1%), a

178 tes and outcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CK

179 MI (NSTEMI) versus ST-segment-elevation MI (STEMI) over time.

180 Primary PCI is successful in most STEMI-SCAD patients, with low 3-year mortality.

181 ime to a comprehensive focus on multifaceted STEMI care offers an opportunity to further improve STEM

182 rdial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI

183 vation myocardial infarction [STEMI] and non-STEMI [NSTEMI]) and subsequently evaluated for sex-based

184 evation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving tre

185 elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), myocardial infarction of unknown type, o

186 s with presumptive COVID-19 with nonanterior STEMI without cardiogenic shock, PPCI offered a 0.4% abs

187 n epicardial coronary vessel is the cause of STEMI in the majority of cases.

188 The diagnosis of STEMI and cardiogenic shock in older patients decreased

189 ncremental prognostic value of each facet of STEMI care on clinical outcomes within a STEMI system of

190 Conclusions Almost one-half of STEMI patients by 2017 were discharged on ticagrelor whi

191 tals in the United Kingdom within 6 hours of STEMI due to a proximal-mid-vessel occlusion of a major

192 urce-appropriate paradigms for management of STEMI in LMICs.

193 CI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolysis therapy should be administ

194 nt has dramatically improved the outcomes of STEMI in high-income countries.

195 revascularization strategies and outcomes of STEMI-SCAD with STEMI atherosclerosis (STEMI-ATH).

196 been gained regarding the pathophysiology of STEMI and feed into the development of new treatment str

197 r adjusting for known clinical predictors of STEMI in-hospital mortality, achievement of at least 2 S

198 e fatty acids might improve the prognosis of STEMI.

199 pulation data to generate incidence rates of STEMI.

200 e the effect of smoking on increased risk of STEMI between sexes.

201 men having a significantly increased risk of STEMI than men.

202 ents who had cardiac arrest without signs of STEMI to undergo immediate coronary angiography or coron

203 -hospital cardiac arrest and had no signs of STEMI, a strategy of immediate angiography was not found

204 tors showed that serum-PC EPA at the time of STEMI was inversely associated with both incident MACE a

205 e omega-3 consumption) levels at the time of STEMI were associated with a lower incidence of major ad

206 d serum-PC EPA and ALA levels at the time of STEMI were associated with a lower risk of clinical adve

207 elMed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118).

208 eLmed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118).

209 (AngeLmed Early Recognition and Treatment of STEMI) pivotal study, subjects at high risk for recurren

210 elMed for Early Recognition and Treatment of STEMI), a multicenter, randomized trial of an implantabl

211 s the persistently dramatic impact of SCA on STEMI and the major importance of PCI in this setting.

212 myocardial infarction (STEMI); however, once STEMI occurs, smoking has been associated with favorable

213 Peak STEMI rate for current smokers was in the 70 to 79 years

214 ients with left ventricular dysfunction post STEMI who are at risk for death and major morbidity.

215 ients with left ventricular dysfunction post STEMI.

216 apping performed at 2 days and 6 months post-STEMI.

217 rct size and thereby reduce the risk of post-STEMI complications and heart failure.

218 oline administration in the early phase post-STEMI in patients with multivessel disease is safe.

219 f patients presenting with late presentation STEMI was observed in 2020 compared with the historical

220 Compared with controls, patients with recent STEMI exhibited increased LV wall active tension when no

221 ntion (PCI) are also associated with reduced STEMI mortality.

222 tively analyzed (2003 to 2017) at 2 regional STEMI programs (Minneapolis Heart Institute and Cedars-S

223 Catheterization Laboratory; and 4) Regional STEMI systems of care.

224 specific risk scores to stratify reperfused STEMI patients by their risk level for targeted interven

225 Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly alloc

226 escending culprit and cardiogenic shock than STEMI-ATH.

227 elated functional impairments and, among the STEMI subgroup, a higher incidence of overall bleeding e

228 n on infarct size, we analyzed data from the STEMI-Door to Unload (STEMI-DTU) trial and then tested t

229 Two hundred eighty-three STEMI patients (mean age, 59+/-12 years; 75% male) had c

230 analyzed data from the STEMI-Door to Unload (STEMI-DTU) trial and then tested the effect of LV unload

231 morbidities, including drug and alcohol use, STEMI acuity (cardiac arrest and cardiogenic shock), and

232 , 0.54 [95% CI, 0.36-0.81] P=0.003), whereas STEMI increased the risk of all-cause death (hazard rati

233 icantly lower in patients with COVID-19 with STEMI.

234 A total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial.

235 that utilization of PCI in older adults with STEMI and cardiogenic shock is increasing and paralleled

236 nary intervention (PCI) in older adults with STEMI and shock and its influence on in-hospital mortali

237 y over time (proportion of older adults with STEMI and shock: 1999: 42% vs. 2013: 29%).

238 justed analyses, Medicaid beneficiaries with STEMI had lower rates of coronary revascularization (88.

239 Medicaid beneficiaries with STEMI had lower rates of revascularization, although sma

240 ortality at hospital discharge compared with STEMI without SCA.

241 Compared with STEMI-ATH, STEMI-SCAD patients were younger (age 49 +/-

242 older with symptoms or signs consistent with STEMI at primary care clinics, small hospitals, and PCI

243 Of the 317,728 encounters with STEMI and shock in the United States, 111,901 (35%) were

244 tality among the renal transplant group with STEMI was markedly lower compared with the stage 5D CKD

245 ) were identified who were hospitalized with STEMI.

246 A total of 2420 patients with STEMI (2034 men [84.0%] and 386 women [16.0%]; mean [SD]

247 ively included 944 consecutive patients with STEMI (mean age 61 years, 209 women) undergoing primary

248 or in 30-day mortality of all patients with STEMI (patients who did and did not undergo PCI, 10.86%

249 mortality than did men in both patients with STEMI (women, 9.4%, versus men, 4.5%) and patients with

250 Milan included all consecutive patients with STEMI admitted to our institute from February 21 to Apri

251 Patients with STEMI and another coronary artery lesion in a different

252 wing culprit-lesion PCI, 4,041 patients with STEMI and multivessel CAD were randomized to staged nonc

253 We randomly assigned patients with STEMI and multivessel coronary artery disease who had un

254 Among patients with STEMI and multivessel coronary artery disease, complete

255 We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary

256 In patients with STEMI and multivessel disease who underwent primary PCI

257 esults were consistent between patients with STEMI and those with NSTEMI and across other major subgr

258 ated that soluble cytokines in patients with STEMI are upregulated in a coordinated fashion in contra

259 nonculprit artery territory in patients with STEMI are very common.

260 ive cases of COVID-19-positive patients with STEMI compared with COVID-19-negative patients.

261 et to hospital admission among patients with STEMI during COVID-19 pandemic compared with the same ti

262 to assess clinical features of patients with STEMI during COVID-19 pandemic.

263 In conclusion, the patients with STEMI had serial changes in cardiac complexity.

264 Patients with STEMI in SOS hospitals had significantly lower 2-year re

265 in use of P2Y12 inhibitors in patients with STEMI in the United States.

266 n LD of ticagrelor, 180 mg, in patients with STEMI is feasible and facilitates better early platelet

267 Patients with STEMI presenting with concurrent COVID-19 infection had

268 Importantly, patients with STEMI presenting with COVID-19 infection had a longer in

269 day mortality was compared for patients with STEMI regardless of whether they underwent PCI.

270 n the treatment and outcome of patients with STEMI treated by primary percutaneous coronary intervent

271 Of 1272 consecutive patients with STEMI treated with PCI at our hospital (January 1, 2011,

272 lume PPCI centers and assessed patients with STEMI treated with PPPCI in March/April 2019 and 2020.

273 heart failure) at 12 months in patients with STEMI undergoing PPCI.

274 METHODS AND First patients with STEMI undergoing primary percutaneous coronary intervent

275 d from 10 randomized trials of patients with STEMI undergoing primary percutaneous coronary intervent

276 In patients with STEMI who were being transported for primary percutaneou

277 -invasive strategy in selected patients with STEMI with presumptive COVID-19 and low likelihood of mo

278 er mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEM

279 ing and delayed reperfusion in patients with STEMI without cardiogenic shock is safe and feasible.

280 still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mo

281 Among 2,564 patients with STEMI, 1,093 (42.6%) were recent smokers.

282 Participants included 3602 patients with STEMI, aged 18 years or older, who were undergoing prima

283 volunteers without CVD and 62 patients with STEMI, separated soluble and EV fractions, and analyzed

284 For patients with STEMI, there were no significant mortality differences b

285 a reperfusion therapy in adult patients with STEMI, whether given alone or in combination with adjunc

286 ant impact on the treatment of patients with STEMI, with a 19% reduction in PPCI procedures, especial

287 ere lower in SOS hospitals for patients with STEMI.

288 iveness of sonothrombolysis in patients with STEMI.

289 xpressed almost exclusively in patients with STEMI.

290 om 12% (1995) to 76% (2015) in patients with STEMI.

291 our after LD administration in patients with STEMI.

292 ferred reperfusion strategy in patients with STEMI; if PCI cannot be performed within 120 minutes of

293 om 66+/-14 to 63+/-14 years in patients with STEMI; it remained stable (68+/-14 years) in patients wi

294 y With PCI Versus PCI Alone in Patients With STEMI]) enrolled 19 047 patients, of whom 18 306 underwe

295 In patients presenting with STEMI and concurrent COVID-19 infection, there is a stro

296 egy in the majority of cases presenting with STEMI in the setting of the COVID-19 pandemic.

297 Among renal transplant recipients with STEMI, the use of reperfusion increased from 53.7% in th

298 n strategies and outcomes of STEMI-SCAD with STEMI atherosclerosis (STEMI-ATH).

299 tes of bleeding were higher among women with STEMI (26.2% versus 15.6%, P<0.001) but not NSTEMI (17.8

300 r all patients with PCI and patients without STEMI, there were no significant differences in in-hospi